Evidence map›Paper›PMID 35882213›Full record

ArticleUrologia internationalis2023

Epidemiology of Unconventional Histological Subtypes of Urethral Cancer.

Mike Wenzel, Claudia Collà Ruvolo, Christoph Würnschimmel, Luigi Nocera, Benedikt Hoeh, Zhe Tian, Fred Saad, Alberto Briganti, Derya Tilki, Severiné Banek and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Urologia internationalis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Mike WenzelDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Claudia Collà RuvoloCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Christoph WürnschimmelCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Luigi NoceraCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Benedikt HoehDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Zhe TianCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Alberto BrigantiDivision of Experimental Oncology, Department of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Severiné BanekDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Philipp MandelDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Andreas BeckerDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Luis A KluthDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Felix K H ChunDepartment of Urology, University Hospital Frankfurt, Goethe Universtity Frankfurt, Frankfurt am Main, Germany.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Goethe University Frankfurt · DEUniversité de Montréal · CAIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of the study was to examine cancer-specific mortality (CSM) of unconventional urethral cancers.

methodsWithin the SEER (2004-2016) database, we analyzed CSM of 165 patients with unconventional urethral-cancer histology. Kaplan-Meier plots were used to test the effect of unconventional histologies in urethral cancer on CSM.

resultsOf 165 eligible patients, the Mullerian type accounted for 55 (33.3%) versus melanocytic (26.7%) versus neuroendocrine 25 (15.2%) versus lymphoma 22 (13.3%) versus mesenchymal/sarcoma 15 (9.1%) versus spindle cell 4 (2.1%) patients. Median age at diagnosis was 81 years in spindle cell, 75 in melanocytic, 74 in neuroendocrine and mesenchymal/sarcoma, 67 in lymphoma, and 62 years Mullerian type (p < 0.001). Of all, 116 (70.3%) were female. The Mullerian type exhibited the highest female ratio (96.4%) versus the lowest female ratio in neuroendocrine (24.0%). The Mullerian type was most frequent in African-American females. In Caucasian females, the melanocytic type was most frequent (49.1%). In African-American (38.9%) and Caucasian males (33.3%), neuroendocrine histology was most frequent. Three-year CSM was, respectively, 27.5%, 23.1% 22.3%, 20.5%, and 16.1% for melanocytic, mesenchymal/sarcoma, Mullerian type, neuroendocrine, and lymphoma histology. Median cancer-specific survival was 106 versus 10 months for combined nonmetastatic versus metastatic nonconventional histologies.

conclusionImportant age, sex, racial/ethnic group distribution, and survival differences exist between each unconventional urethral-cancer histological subtypes.

Indexed as

SarcomaUrethral NeoplasmsFemaleHumansMaleSEER ProgramLymphomaMelanocytic typeMullerian typeNeuroendocrineSarcomaSpindle cell

Identifiers

PMID35882213
PMCPMC9909713
OpenAlexW4288181014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.